Abstract:

Application of preoperative target therapy and the timing of surgery for gastrointestinal stromal tumor        LI Zi-yu, LI Shuang-xi, JI Jia-fu.Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education)；Department of Gastrointestinal Surgery, Peking University Cancer Hospital & Institute, Beijing 100142, China
Corresponding author: LI Zi-yu, E-mail: ziyu_li@hsc.pku.edu.cn
Abstract    With the progression in pathogenesis and drug developments, the emergence of small molecule tyrosine kinase inhibitor (imatinib) changed the treatment modality of gastrointestinal stromal tumors (GIST), which centered on surgery mainly in the past. For the locally advanced or metastatic disease, the preoperative treatment could increase resection rate, preserve organ function, decrease recurrence, and even bring survival benefits. However, preoperative treatment of GIST still lacks large sample prospective randomized study data. Various studies have significant differences in patients' enroll standard, dosage, time, evaluation and adjuvant therapy. There are still many controversies about the duration of the preoperative treatment of GIST and timing of surgery.

Key words: gastrointestinal stromal tumor, preoperative treatment, neoadjuvant treatment, conversion treatment, target therapy

摘要：

随着发病机制及药物研究的进展，小分子酪氨酸激酶抑制剂（伊马替尼）的出现改变了传统的以手术切除为主的胃肠间质瘤（GIST）治疗模式。对于局部进展期或晚期GIST，术前治疗的应用可能提高手术切除率，保存器官功能，降低复发率，甚至带来生存获益。然而GIST的术前治疗仍缺乏大样本的前瞻随机研究数据。各研究在病人入排标准、药物剂量、时间、评效及辅助治疗方面差异较大。关于GIST术前治疗的持续时间及手术时机仍存在广泛争议。

关键词: 胃肠间质瘤, 术前治疗, 新辅助治疗, 转化治疗, 靶向治疗